SOMAÍ Pharmaceuticals

Who are we? SOMAÍ Pharmaceuticals is a leading EU-GMP European vertically integrated Multi-Country Operator (MCO) company with a global footprint of distribution for the largest and most advanced EU GMP-certified cannabinoid-containing pharmaceutical extract portfolio. SOMAÍ owns a state-of-the-art manufacturing facility and indoor cultivation in Lisbon, Portugal, and has global sales teams in the largest medical cannabis markets. We are continuing to make acquisitions and global brand partnerships that make us one of a few and the first European-based vertically integrated companies in the EU able to cater to the diverse needs of fast-growing global cannabis markets. In this video, Michael Sassano, Founder and Interim CEO of SOMAÍ, and Rita Barata, Chief Marketing Officer, take CannaReporter on a tour of SOMAÍ's state-of-the-art facilities in Portugal, explaining SOMAÍ story, values, and future projects for the company. This video is an advertising mini-doc and was made by the CannaReporter® Commercial and Marketing department. #SOMAÍ #GMP #medicalcannabis #biotechnology #medicalcannabismarket #manufacturing #pharmtech #medicalcannabisnews 

Spain has become the latest large European country to announce its long-awaited medical cannabis access plans. Although this is just the first step toward parliamentary procedures, it marks definitive progress for Spain. The proposal does not mention flower sales, seemingly favoring extract producers. The emphasis on non-flower cannabis products is not surprising, given the debate over the last few years and the proliferation of cannabis social clubs. Ultimately, patients deserve access to safer alternatives to current over-prescribed pharmaceutical medicines. Read the latest article by Michael Sassano published in Legal Reader: https://lnkd.in/dU5yfAvQ #SOMAÍ #GMP #medicalcannabis #biotechnology #medicalcannabismarket #manufacturing #pharmtech #medicalcannabisnews 

This past week, our company gathered to celebrate our collective successes and the incredible journey we've been on. SOMAÍ now has a dedicated team of 120 individuals working tirelessly to create a healthier future for patients worldwide. Each member of the SOMAÍ team brings something unique to the table, and this diversity makes our company truly exceptional. Here's to many more achievements and celebrations together! #SOMAÍ #GMP #medicalcannabis #biotechnology #medicalcannabismarket #manufacturing #pharmtech #medicalcannabisnews 

August marks Gastroparesis Awareness Month, an initiative established by the International Foundation for Gastrointestinal Disorders (IFFGD) in 2016 to educate the public about gastroparesis, stress the importance of early diagnosis, and advocate for better treatment options. Gastroparesis, also known as delayed gastric emptying, is a chronic disorder that can significantly impact one's quality of life, with symptoms ranging from mild to severe. Gastroparesis is characterized by delayed stomach emptying, leading to a variety of symptoms such as: - Nausea and vomiting; - Stomach pain and discomfort; - Dry heaves - Feeling full after a small meal; - Bloating, loss of appetite, and heartburn. Unmanaged gastroparesis can lead to severe complications like dehydration, nutritional deficiencies, and emotional challenges. The unpredictability of symptoms can interfere with daily activities and impose a significant financial burden. A 2019 study found that 12% of patients with gastroparesis use cannabis, particularly those with severe nausea and abdominal pain. Many of these patients reported significant benefits from cannabis, with 81% rating their symptoms as better or much better. However, more research is needed to fully understand the efficacy and safety of medicinal cannabis for gastroparesis. It's crucial to consult your doctor before considering cannabis as a treatment option. Source: H.P. Parkman, E. P. Sharkey, Linda A. Nguyen, K. P. Yates, T. L. Abell, W. L. Hasler, W. Snape, J. Clarke, R. Schey, K. L. Koch, B. Kuo, R. W. McCallum, I. Sarosiek, M. Grover, G. Farrugia, J. Tonascia, P. J. Pasricha & Frank A. Hamilton for the NIH Gastroparesis Consortium. Marijuana Use in Patients with Symptoms of Gastroparesis: Prevalence, Patient Characteristics, and Perceived Benefit. Digestive Diseases and Sciences, 2020, Volume 65, pages 2311–2320 #SOMAÍ #medicalcannabis #pharmtech

The United States Department of Health and Human Services (HHS) report stating that cannabis is safe and effective for at least 15 indications was a shot in the arm for all regulators looking to change cannabis policy in their countries. Germany, the largest European Union country and one of the most influential, decriminalized cannabis and removed it from the narcotics listing. Germany’s policy movements have sent many other EU countries scrambling to create policies for safe cannabis consumption. Additionally, the high probability of the U.S. rescheduling cannabis to a Schedule III medicine will undoubtedly continue shifting the global medical cannabis landscape. These changes are leading investors and companies to invest heavily in the global medical cannabis markets. Some of the hottest trends in those international medical cannabis markets are the upward trajectories of clinics, dispensaries and edibles. Read the latest article by Michael Sassano published in krautinvest.de: https://lnkd.in/dM7t9kHX #SOMAÍ #GMP #medicalcannabis #biotechnology #medicalcannabismarket #manufacturing #pharmtech #medicalcannabisnews 

SOMAÍ Pharmaceuticals is proud to announce the Mint Oral Solutions product line launch in Australia, Germany, and the UK. SOMAÍ constantly focuses on patients' needs and preferences to produce innovative, improved performance and tasting products. The new line includes single-strain oils infused with peppermint terpene mixes in various dosage forms, from CBD-dominant to balanced and high-THC. The mint line is the first introduction to improve patients' compliance and treatment adherence, combining purified extracts and a subtle aromatic mint taste. "Cannabis patients prioritize the products' performance, smell, and taste," said Michael Sassano, the founder and interim CEO of SOMAI Pharmaceuticals. "So as we prioritize improving patient experience, mint is an excellent starting experience as a popular blend with calming and therapeutic effects, as well as a pleasant subtle taste." More information: https://lnkd.in/dRzAMnm6 #SOMAÍ #GMP #medicalcannabis #biotechnology #medicalcannabismarket #manufacturing #pharmtech #medicalcannabisnews 

🚀 Just 3 Days to Go! ! 🚀 Join us at "A holistic Approach to Healthcare" 📅 Date: July 25th, 2024 🕠 Time: 5:30 PM - 8:00 PM 📍 Location: Health104 - "The Gallery" Level 3, 104 Canterbury Rd, Middle Park, VIC, 3206 💲 Free 1. Network with you fellow doctors over drinks and nibbles 2. Discover how StatDoctor is bringing technology to doctors 3. Learn about Health104, their technology and their holistic experience 4. Explore how SOMAÍ Pharmaceuticals's innovative formulations are improving patient outcomes Ft. Special guest speaker Dr Mihindu Jayasuriya! 📩 RSVP Today: https://lnkd.in/gCu5JGzN Don't miss this opportunity to be part of the future of healthcare! #HealthcareInnovation #HolisticMedicine #StatDoctor #Health104 #Somaipharmaceuticals #HealthTech #NetworkingEvent

Chairman and interim chief executive Michael Sassano said: “We are keeping our promise to Australia to build massive inventories of extracts so product never run out for doctors. I want us to be known for doing what we say. We are executing on our promise and will continue to support Australia.” Read the full article in Cannabiz: https://lnkd.in/dipWYAvn #SOMAÍ #GMP #medicalcannabis #biotechnology #medicalcannabismarket #manufacturing #pharmtech #medicalcannabisnews 

What is the first thing you do when you open a new bag of cannabis flower? You smell it! Cannabis consumers have always prioritized the products' smell, taste, and performance. Why should extracts be any different? The smell, taste and performance of extracts are just as crucial as flower. Too long have Europeans suffered from bad-tasting extracts. The only reason European medical cannabis extracts taste so bad is that producers have failed to acknowledge consumer preferences and have limited knowledge of the actual processes of extraction. One basic solution? Just put some peppermint terpenes in it! Read the latest article by Michael Sassano in Benzinga: https://lnkd.in/d9AGt8ST #SOMAÍ #GMP #medicalcannabis #biotechnology #medicalcannabismarket #manufacturing #pharmtech #medicalcannabisnews 

At SOMAÍ, we control every step of the manufacturing process to ensure quality and consistency. We create improved-tasting products with stable cannabinoid profiles across different batches. SOMAÍ’s initial extracts, made from the single-strain cannabis flower, will be available in a range of formulations and sizes to suit all patient and practitioner preferences worldwide. For more information, visit our website: somaipharma.eu #SOMAÍ #GMP #medicalcannabis #biotechnology #medicalcannabismarket #manufacturing #pharmtech #medicalcannabisnews